IceCure Medical Ltd - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICCM Nasdaq 3840 www.icecure-medical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IceCure Medical Ltd

IceCure Medical (NASDAQ:ICCM) shareholders have earned a 51% CAGR over the last five years - Jun 28th, 2025 7:02 am
Sector Update: Health Care Stocks Softer Wednesday Afternoon - Jun 25th, 2025 11:44 am
IceCure Medical's Board Approves $10 Million Rights Offering - Jun 25th, 2025 8:31 am
IceCure Announces Record Date for Rights Offering for Up to $10 Million - Jun 25th, 2025 7:23 am
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes - Jun 9th, 2025 6:30 am
Icecure Medical Ltd (ICCM) Q1 2025 Earnings Call Highlights: Strategic Advances and Market ... - May 29th, 2025 5:00 pm
IceCure Medical Reports First Quarter 2025 Financial Results - May 28th, 2025 6:30 am
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025 - May 21st, 2025 6:30 am
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - May 8th, 2025 3:55 pm
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation - May 6th, 2025 6:30 am
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer - Apr 30th, 2025 6:30 am
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - Apr 28th, 2025 6:30 am
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - Apr 22nd, 2025 6:30 am
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Mar 28th, 2025 7:16 am
IceCure Medical Full Year 2024 Earnings: Misses Expectations - Mar 28th, 2025 5:09 am
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - Mar 27th, 2025 6:30 am
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - Mar 24th, 2025 6:30 am
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - Mar 21st, 2025 6:30 am
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - Mar 20th, 2025 6:30 am
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - Mar 18th, 2025 6:30 am